Bisphosphonates-related jaw osteonecrosis;Ostéonécrose des maxillaires chez des patients traités par bisphosphonates

Presse Medicale

Volumn 34, Issue 15, 2005, Pages 1073-1077

  Najm, Semaan Abi ^a,c   Lysitsa, S ^a   Carrel, J P ^a   Lesclous, P ^b   Lombardi, T ^a   Samson, J ^a  

^a HUG et Faculté de Médecine   (Switzerland)

^b UniversitéParis 5   (France)

^c Chirurgie Orale et Radiologie Dentomaxillo faciale   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; BONE MINERAL; BONE NECROSIS; BONE REMODELING; DISEASE PREDISPOSITION; DRUG EFFECT; HUMAN;

EID: 24944474270     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)84119-3     Document Type: Article

References (23)

1. Rogers MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004; 75: 451-61.
2. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25: 97-106.
3. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459-68.
4. Amital H, Applbaum H, Aamar S, Daniel N, Rubinow A. Sapho syndrome treated with pamidronate: an open-label study of 10 patients. Rhumatology 2004; 43: 658-61.
5. Bezzi M, Hasmim M, Bieler G, Dormond O, Ruegg C. Zolendronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 2003; 278: 43603-14.
6. Recommandations de l'Afssaps. Traitement médicamenteux de l'ostéoporose cortisonique. Med Therap 2004; 10: 63-71.
7. Recommandations de l'Afssaps. Traitement de l'ostéoporose post ménopausique. (actualisation octobre 2004). http.//afssaps.sante.fr/htm/ 5/rbp/indrbp.htm
8. Facon T, Gastinne T, Leleu X. Myélome multiple: espoirs thérapeutiques. Rev Prat 2003; 17: 515-17.
9. Brown JE, Neville-Webbe H, Coleman RE. The role of bisphoshonates in breast and prostate cancers. Endocrine-Related Cancer 2004; 11: 207-24.
10. Agarwala S, Sule A, Pai BU, Joshi VR. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology 2002; 41: 346-7.
11. Marx R. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-17.
12. Ruggiero SL, Mehrotra B, Rosenberg TJ. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-34.
13. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 2003; 48: 268.
14. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253-4.
15. Pogrel A. Bisphosphonates and bone necrosis. J Oral Maxillofac Surg 2004; 62: 391-2.
16. Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 2004; 117: 440-1.
17. Greenberg MS. Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 259-60.
18. Reid IR, Davisdson JS, Wattie D, Wu F, Lucas J, Gamble GD, Rutland MD, Cundy T. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 2004; 35: 224-30.
19. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003; 61: 1238-9.
20. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18: 75-85.
21. Nyman JS, Yeh OC, Hazelwood SJ, Martin RB. A theoretical analysis of long-term bisphosphonate effects on trabecular bone volume and microdamage. Bone 2004; 35: 296-305.
22. Hellstein JW, Marek CL. Bis-phossy jaw, phossy jaw, and the 21st century: bisphosphonate-associated complications of the jaws. J Oral Maxillofac Surg 2004; 62: 1563-66.
23. Starck WJ, Epker BN. Failure of osseointegrated dental implants after diphosphonate therapy of osteoporosis: a case report. Int J Oral Maxillofac Implants 1995; 10: 74-8.